Sanofi, BEYFORTUS
As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...
With the peak flu season often occurring during December and January and even into February, Dr. Sharon Nachman, Chief of the ...
Zacks.com on MSN2d
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock ...
The Nunavut government says it will provide immunization against respiratory syncytial virus to all infants in the territory ...
RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...
Company planning for every eligible baby in the US to have access to BEYFORTUS New BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity ...
Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.
October: time for muddy soccer practices, cider pressing and Halloweentown ... And time to roll up your sleeves.
Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...
With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback